By Ria Kakkad (Drug Target Review)2023-04-11T10:00:40
New research from Cincinnati Children’s Hospital Medical Center suggests blocking IL-22 and IL-1R could offer a promising IBD treatment.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-26T13:58:00Z
2024-01-24T12:52:38
Sponsored by BellBrook Labs
2023-01-05T14:41:33
Sponsored by Cell Signaling Technology
2026-03-25T15:00:00 2026-03-25T16:00:00
Sponsored by Yokogawa
2023-03-03T14:06:14
Sponsored by Bio-Techne
2023-05-18T10:39:07
Sponsored by BPS Bioscience
Site powered by Webvision Cloud